Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice

Kuralay Atageldiyeva, Yukihiro Fujita, Tsuyoshi Yanagimachi, Katsutoshi Mizumoto, Yasutaka Takeda, Jun Honjo, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Masakazu Haneda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A low carbohydrate diet (LCHD) as well as sodium glucose cotransporter 2 inhibitors (SGLT2i) may reduce glucose utilization and improve metabolic disorders. However, it is not clear how different or similar the effects of LCHD and SGLT2i are on metabolic parameters such as insulin sensitivity, fat accumulation, and especially gluconeogenesis in the kidney and the liver. We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. We compared metabolic parameters, gene expression for transcripts related to glucose and fat metabolism, and glycogen content in the kidney and the liver among the groups. SGLT2i but not LCHD improved glucose excursion after an oral glucose load compared to NCHD, although all groups presented comparable non-fasted glycemia. Both the LCHD and SGLT2i treatments increased calorie-intake, whereas only the LCHD increased body weight compared to the NCHD, epididimal fat mass and developed insulin resistance. Gene expression of certain gluconeogenic enzymes was simultaneously upregulated in the kidney of SGLT2i treated group, as well as in the liver of the LCHD treated group. The SGLT2i treated groups showed markedly lower glycogen content in the liver, but induced glycogen accumulation in the kidney. We conclude that LCHD induces deleterious metabolic changes in the non-diabetic mice. Our results suggest that SGLT2i induced gluconeogenesis mainly in the kidney, whereas for LCHD it was predominantly in the liver.

Original languageEnglish
Article numbere0157672
JournalPLoS One
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Sodium-Glucose Transport Proteins
Carbohydrate-Restricted Diet
low carbohydrate diet
Gluconeogenesis
gluconeogenesis
Nutrition
Glycogen
Liver
glycogen
kidneys
Carbohydrates
sodium
Kidney
liver
glucose
mice
Glucose
Fats
Diet
Insulin Resistance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice. / Atageldiyeva, Kuralay; Fujita, Yukihiro; Yanagimachi, Tsuyoshi; Mizumoto, Katsutoshi; Takeda, Yasutaka; Honjo, Jun; Takiyama, Yumi; Abiko, Atsuko; Makino, Yuichi; Haneda, Masakazu.

In: PLoS One, Vol. 11, No. 6, e0157672, 01.06.2016.

Research output: Contribution to journalArticle

Atageldiyeva, Kuralay ; Fujita, Yukihiro ; Yanagimachi, Tsuyoshi ; Mizumoto, Katsutoshi ; Takeda, Yasutaka ; Honjo, Jun ; Takiyama, Yumi ; Abiko, Atsuko ; Makino, Yuichi ; Haneda, Masakazu. / Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice. In: PLoS One. 2016 ; Vol. 11, No. 6.
@article{8b885e0c4cf8409a879f7b949b315fe9,
title = "Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice",
abstract = "A low carbohydrate diet (LCHD) as well as sodium glucose cotransporter 2 inhibitors (SGLT2i) may reduce glucose utilization and improve metabolic disorders. However, it is not clear how different or similar the effects of LCHD and SGLT2i are on metabolic parameters such as insulin sensitivity, fat accumulation, and especially gluconeogenesis in the kidney and the liver. We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. We compared metabolic parameters, gene expression for transcripts related to glucose and fat metabolism, and glycogen content in the kidney and the liver among the groups. SGLT2i but not LCHD improved glucose excursion after an oral glucose load compared to NCHD, although all groups presented comparable non-fasted glycemia. Both the LCHD and SGLT2i treatments increased calorie-intake, whereas only the LCHD increased body weight compared to the NCHD, epididimal fat mass and developed insulin resistance. Gene expression of certain gluconeogenic enzymes was simultaneously upregulated in the kidney of SGLT2i treated group, as well as in the liver of the LCHD treated group. The SGLT2i treated groups showed markedly lower glycogen content in the liver, but induced glycogen accumulation in the kidney. We conclude that LCHD induces deleterious metabolic changes in the non-diabetic mice. Our results suggest that SGLT2i induced gluconeogenesis mainly in the kidney, whereas for LCHD it was predominantly in the liver.",
author = "Kuralay Atageldiyeva and Yukihiro Fujita and Tsuyoshi Yanagimachi and Katsutoshi Mizumoto and Yasutaka Takeda and Jun Honjo and Yumi Takiyama and Atsuko Abiko and Yuichi Makino and Masakazu Haneda",
year = "2016",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0157672",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice

AU - Atageldiyeva, Kuralay

AU - Fujita, Yukihiro

AU - Yanagimachi, Tsuyoshi

AU - Mizumoto, Katsutoshi

AU - Takeda, Yasutaka

AU - Honjo, Jun

AU - Takiyama, Yumi

AU - Abiko, Atsuko

AU - Makino, Yuichi

AU - Haneda, Masakazu

PY - 2016/6/1

Y1 - 2016/6/1

N2 - A low carbohydrate diet (LCHD) as well as sodium glucose cotransporter 2 inhibitors (SGLT2i) may reduce glucose utilization and improve metabolic disorders. However, it is not clear how different or similar the effects of LCHD and SGLT2i are on metabolic parameters such as insulin sensitivity, fat accumulation, and especially gluconeogenesis in the kidney and the liver. We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. We compared metabolic parameters, gene expression for transcripts related to glucose and fat metabolism, and glycogen content in the kidney and the liver among the groups. SGLT2i but not LCHD improved glucose excursion after an oral glucose load compared to NCHD, although all groups presented comparable non-fasted glycemia. Both the LCHD and SGLT2i treatments increased calorie-intake, whereas only the LCHD increased body weight compared to the NCHD, epididimal fat mass and developed insulin resistance. Gene expression of certain gluconeogenic enzymes was simultaneously upregulated in the kidney of SGLT2i treated group, as well as in the liver of the LCHD treated group. The SGLT2i treated groups showed markedly lower glycogen content in the liver, but induced glycogen accumulation in the kidney. We conclude that LCHD induces deleterious metabolic changes in the non-diabetic mice. Our results suggest that SGLT2i induced gluconeogenesis mainly in the kidney, whereas for LCHD it was predominantly in the liver.

AB - A low carbohydrate diet (LCHD) as well as sodium glucose cotransporter 2 inhibitors (SGLT2i) may reduce glucose utilization and improve metabolic disorders. However, it is not clear how different or similar the effects of LCHD and SGLT2i are on metabolic parameters such as insulin sensitivity, fat accumulation, and especially gluconeogenesis in the kidney and the liver. We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. We compared metabolic parameters, gene expression for transcripts related to glucose and fat metabolism, and glycogen content in the kidney and the liver among the groups. SGLT2i but not LCHD improved glucose excursion after an oral glucose load compared to NCHD, although all groups presented comparable non-fasted glycemia. Both the LCHD and SGLT2i treatments increased calorie-intake, whereas only the LCHD increased body weight compared to the NCHD, epididimal fat mass and developed insulin resistance. Gene expression of certain gluconeogenic enzymes was simultaneously upregulated in the kidney of SGLT2i treated group, as well as in the liver of the LCHD treated group. The SGLT2i treated groups showed markedly lower glycogen content in the liver, but induced glycogen accumulation in the kidney. We conclude that LCHD induces deleterious metabolic changes in the non-diabetic mice. Our results suggest that SGLT2i induced gluconeogenesis mainly in the kidney, whereas for LCHD it was predominantly in the liver.

UR - http://www.scopus.com/inward/record.url?scp=84976904194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976904194&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0157672

DO - 10.1371/journal.pone.0157672

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0157672

ER -